Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
Hepatic disease refers to various disorders that impair or prevent the liver from functioning properly. Yellowing of the skin or eyes (jaundice), abdominal pain, or abnormal liver function test results may indicate liver illness. Common liver ailments include cancer, hepatitis, autoimmune diseases, and genetic problems.
The rise in the prevalence of liver diseases, such as non-alcoholic fatty liver disease (NAFLD), liver cirrhosis, hepatitis, alcoholic hepatitis, and liver cancer worldwide is largely due to an unhealthy lifestyle and excessive alcohol consumption. The high burden of liver disease is propelling the demand for the hepatic disease treatment market. One of the primary factors augmenting the market growth is the increasing geriatric population, which is susceptible to a variety of chronic diseases, including liver disease. Moreover, the quick acceptance of antiviral medications, which are safe and efficient in suppressing the hepatitis B virus and lowering the risk of developing cirrhosis and hepatocellular carcinoma, is favorably influencing the market growth.
Further, increasing research and development activities, significant growth in the healthcare industry, and implementation of various government initiatives in order to promote public health are creating a positive outlook for the hepatic disease treatment market value. For instance, the Indian government announced the integration of non-alcoholic fatty liver disease (NAFLD) with the National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS). This program is mainly focused on early diagnosis and management of NAFLD, along with building healthcare infrastructure for the prevention, diagnosis, and treatment of NAFLD. Additionally, the development of novel therapeutics and advancements in diagnostic techniques are some of the factors aiding the market expansion.
Increasing Prevalence of Liver Diseases to Affect the Market Landscape Significantly
Recent studies reveal that liver disease is responsible for 2 million deaths every year and accounts for 4% of all deaths worldwide (1 in every 25 deaths). It is reported that roughly two-thirds of all liver-related deaths occur in males. Liver cancer also poses a significant health challenge, causing 600,000 to 900,000 deaths annually, primarily as a result of cirrhosis and hepatocellular carcinoma . According to the American Cancer Society, the year 2024 will witness the diagnosis of around 41,630 individuals with primary liver cancer and intrahepatic bile duct cancer in the United States. Further, it is also estimated that 29,840 individuals will die from these cancers , indicating the need for effective medications to combat this liver disease. Thus, the rising burden of liver diseases is set to bolster the growth and innovation in the market.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Key Trends | Impact |
Advancements in Diagnostic Technologies | One of the major market trends is the rising improvements in diagnostic technologies such as imaging techniques (MRI, CT scans) and biomarker-based tests. These advancements help in the early and accurate diagnosis of liver diseases. |
Increased Investment in R&D | Increased funding and grants for research and development of hepatic disease treatments by the government and healthcare organizations is a major market trend. This investment is expected to accelerate the discovery and commercialization of new and effective therapies, which is anticipated to boost the hepatic disease treatment market value. |
Growing Regulatory Support | The market benefits from the presence of a favorable regulatory environment, with regulatory bodies offering orphan drug designations and incentives for novel therapies that are designed to treat rare liver diseases. In addition, the implementation of fast-track and accelerated approval processes is anticipated to support market expansion in the forecast period. |
Heightened Public Awareness | The market is witnessing heightened public awareness regarding liver diseases and their treatments which is prompting more individuals to seek medical attention. This trend is supported by rising public health campaigns and education programs aimed at highlighting the importance of early intervention and adherence to treatment protocols. |
Market Breakup by Treatment Type
Market Breakup by Disease Type
Market Breakup by Route of Administration
Market Breakup by Region
The Antiviral Drugs Segment Based on Treatment Type is Anticipated to Witness Substantial Growth
Based on the treatment type, the market is segmented into antiviral drugs, monoclonal antibodies, immunosuppressant drugs, vaccines, corticosteroid drugs, targeted therapy, and others. The antiviral drugs segment holds a high market value which can be attributed to the high prevalence of viral hepatitis such as hepatitis B and C which can result in chronic liver diseases, cirrhosis, and liver cancer. The chronic nature of these hepatic diseases drives the need for long-term antiviral treatment.
The United States represents a major market for hepatic disease treatment owing to the high prevalence of liver diseases including hepatitis B and C. According to the Centers for Disease Control and Prevention, roughly 800,000 to 1.4 million Americans have chronic hepatitis B virus (HBV) infection, and hepatitis B is the underlying cause of 2,000 to 4,000 fatalities in the United States each year. The increasing number of cases of such liver diseases propels the demand for effective treatments and therapeutics in the region. India is also projected to have substantial market growth in the forecast period owing to improvements in healthcare infrastructure, rising spending on healthcare services, and increased government funds and grants for research and development of hepatic disease treatments.
The key features of the market report comprise the patent analysis, clinical trial analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
AbbVie Inc.
American pharmaceutical company AbbVie is a major market player and invests heavily in R&D to develop innovative therapies for hepatic diseases. The company is known for its combination therapies to treat chronic hepatitis C virus (HCV) infection such as its FDA-approved combination drug MAVYRET (glecaprevir/pibrentasvir).
Merck & Co., Inc.
United States-based Merck & Co., focuses on developing novel treatments for liver diseases, including both antivirals and vaccines. The company is also involved in health initiatives aimed at eliminating hepatitis.
F. Hoffmann-La Roche Ltd
Swiss multinational holding healthcare company Roche is engaged in advancing its pipeline of hepatic disease treatments. Its drug Pegasys (peginterferon alfa-2a) is often used in combination with other antiviral medications to treat chronic hepatitis B and C infections.
Eli Lilly and Company
Headquartered in Indiana (United States), pharmaceutical giant Eli Lilly and Company is one of the key players in the market. It is focused on developing treatments that target liver cancer and fibrosis.
Other key players in the market include Bristol-Myers Squibb Company, Gilead Sciences, Inc., Novartis AG, Takeda Pharmaceuticals Company Ltd., Otsuka Holdings, and GSK PLC.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Treatment Type |
|
Breakup by Disease Type |
|
Breakup by Route of Administration |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share